| Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants (NCT07744802) | Deciphera Pharmaceuticals, LLC | 2026-08-01 |
| Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel) (NCT07539090) | Deciphera Pharmaceuticals, LLC | 2026-06-05 |
| Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) (NCT07158411) | Deciphera Pharmaceuticals, LLC | 2025-11-20 |
| Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate (NCT07158398) | Deciphera Pharmaceuticals, LLC | 2025-10-31 |
| MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib (NCT07075471) | Deciphera Pharmaceuticals, LLC | 2025-09-03 |
| Study of DCC-2812 in Participants With Advanced Genitourinary Cancers (NCT06966024) | Deciphera Pharmaceuticals, LLC | 2025-08-27 |
| A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) (NCT06630234) | Deciphera Pharmaceuticals, LLC | 2024-12-10 |
| Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway (NCT06287463) | Deciphera Pharmaceuticals, LLC | 2024-05-14 |
| A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (NCT05734105) | Deciphera Pharmaceuticals, LLC | 2023-12-13 |
| A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies (NCT05957367) | Deciphera Pharmaceuticals, LLC | 2023-09-28 |
| Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) (NCT05080621) | Deciphera Pharmaceuticals, LLC | 2021-11-01 |
| Study of Vimseltinib for Tenosynovial Giant Cell Tumor (NCT05059262) | Deciphera Pharmaceuticals, LLC | 2021-10-14 |
| A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST (NCT04530981) | Deciphera Pharmaceuticals, LLC | 2021-09-22 |
| Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors (NCT04892017) | Deciphera Pharmaceuticals, LLC | 2021-06-15 |
| A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (NCT03673501) | Deciphera Pharmaceuticals, LLC | 2019-02-08 |
| A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors (NCT03717415) | Deciphera Pharmaceuticals, LLC | 2019-01-02 |
| A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors (NCT03601897) | Deciphera Pharmaceuticals, LLC | 2018-10-25 |
| Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (NCT03353753) | Deciphera Pharmaceuticals, LLC | 2018-02-27 |